723 / 1266
Three drugs selected
•
ERLOTINIB to target EGFR
–
Geoerger N0 2010 and others.
•
EVEROLIMUS to target mTOR pathway
–
Geoerger EJC 2011 in recurrent DIPG.
•
DASATINIB to target PDGFRA pathway
–
Broniscer CCR 2013 in combo with vandetanib
together with RT in newly diagnosed pts.
–
Dasatinib is also targeting other TKI.